NCT06613737View on ClinicalTrials.gov

Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain

NACompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 11, 2024

Primary Completion Date

March 10, 2025

Study Completion Date

March 10, 2025

Conditions
Influenza A H3N2
Interventions
OTHER

Influenza A H3N2 virus dose arm 1

Medium dose, approximately 10\^4.5 TCID50/mL

OTHER

Influenza A H3N2 virus dose arm 2

High dose, approximately 10\^5.5 TCID50/mL

OTHER

Influenza A H3N2 virus dose arm 3

TBD, depending on outcome of Part A

Trial Locations (1)

E14 5NR

hVIVO Services Ltd, 40 Bank Street, London

Sponsors

Lead Sponsor

Hvivo
All Listed Sponsors
lead

Hvivo

INDUSTRY